skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

What do parents want from their child's asthma treatment?

(2132) Views  (385) Full article downloads

Authors: Stefan Walzer

Published Date February 2007 Volume 2007:3(1) Pages 167 - 175
DOI: http://dx.doi.org/10.2147/TCRM.S

Stefan Walzer

Analytica International, Untere Herrenstrasse 25, 79539 Loerrach, Germany

Background: Nearly 5 million children in the United States are affected by asthma, which is more than 5% of the population younger than 18 years. In children four years or younger, the prevalence increased 160% from 1980 to 1994. There are several effective drugs that relieve the symptoms of asthma and others are currently being developed, but even when these medications are prescribed, they may be underutilized because parents fear the possibility of adverse events. Up to now there is no knowledge which are the main drivers of caregiver’s preferences for a safe and effective medication for preschool children in general. The study population was caregivers with children aged 4 years or below. Sample size was 42; results were checked by Monte Carlo simulation.

Material and methods: For a conjoint analysis a status quo treatment and hypothetical treatment options were defined by four attributes: Episode-free days, risk of exacerbation, information available for the long-term impact of the treatment, and out-of-pocket expenses. It was possible to use the status quo as the reference scenario, permitting to couch this ranking in terms of a decision to purchase the product. Relative importances for each product attribute as well as utility estimations for each attribute level were calculated.

Results and discussion: The overall result was that the most important feature for an asthma treatment, in this study, was the attribute of episode-free days. On a scale from 0 to 100 this attribute got the calculated relative importance of 44.2. In contrast to this finding is the relative importance of the attribute EXACERBATION, which only reached 16.2, which is the most unimportant attribute of the attributes offered. Even the variable INFORMATION available on long-term effects in children between 4 years and 14 years of age was more important than the side effects (19.2). Out-of-pocket expenses per month were the second most (relative) important attribute (20.5).

Keywords: utility, conjoint analysis, preference study, health economics, discrete-choice analysis








Readers of this article also read:

Asthma exacerbations: prevention is better than cure
Effectiveness and safety of levosulpiride in the treatment of dysmotility-like functional dyspepsia
Hypokalemia secondary to capecitabine: a hidden toxicity?
Long-term management of gastroesophageal reflux disease with pantoprazole
A smarter way to manage asthma with a combination of a long-acting β2-agonist and inhaled corticosteroid
Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom
Fosphenytoin for the treatment of status epilepticus: an evidence-based assessment of its clinical and economic outcomes
Immunological and genetic aspects of asthma and allergy
Nanostructured delivery system for zinc phthalocyanine: preparation, characterization, and phototoxicity study against human lung adenocarcinoma A549 cells
The impact of vitamin D deficiency on immune T cells in asthmatic children: a case-control study